Oyster Point Pharma, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: San Francisco CA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03452397
First Marketed Drug
2021
varenicline (chantix)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

OYSTER POINT PHARMA | Oyster Point Pharma, Inc.